---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-25-000084"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T03:51:05.827883+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics Q1 net loss $17.7M; cash $182.1M; Phase 3 AURORA on track

## Summary
- Net loss of $17.7M ($0.68 basic loss per share) vs $56.8M ($10.50) in Q1 2024; R&D expenses rose to $14.7M.
- Cash, equivalents and restricted cash $182.1M as of March 31, 2025; expected to fund operations into mid-2027.
- Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) expected to begin in Q2 2025 with ~100 participants.
- Phase 2b data showed sustained MG-ADL reduction of 4.8 points at Month 12; deeper 7.1-point drop in biologic-naïve subgroup.
- Preliminary Phase 2 SLE data and Phase 2 pediatric basket trial initiation expected in H2 2025.

## SEC filing metadata
- accession: 0001453687-25-000084
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000084/0001453687-25-000084-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000084/rnac-20250508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-25-000084
- JSON: https://secwatch.observer/filing/0001453687-25-000084.json
- Plain text: https://secwatch.observer/filing/0001453687-25-000084.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.